收费全文 | 160941篇 |
免费 | 31936篇 |
国内免费 | 2420篇 |
耳鼻咽喉 | 5372篇 |
儿科学 | 5653篇 |
妇产科学 | 2592篇 |
基础医学 | 4492篇 |
口腔科学 | 1777篇 |
临床医学 | 27859篇 |
内科学 | 49039篇 |
皮肤病学 | 7569篇 |
神经病学 | 15760篇 |
特种医学 | 6655篇 |
外国民族医学 | 2篇 |
外科学 | 42242篇 |
综合类 | 396篇 |
现状与发展 | 72篇 |
一般理论 | 15篇 |
预防医学 | 8188篇 |
眼科学 | 3648篇 |
药学 | 1679篇 |
中国医学 | 20篇 |
肿瘤学 | 12267篇 |
2024年 | 688篇 |
2023年 | 4820篇 |
2022年 | 1291篇 |
2021年 | 3306篇 |
2020年 | 6164篇 |
2019年 | 2365篇 |
2018年 | 7589篇 |
2017年 | 7503篇 |
2016年 | 8606篇 |
2015年 | 8627篇 |
2014年 | 15772篇 |
2013年 | 16031篇 |
2012年 | 6061篇 |
2011年 | 6061篇 |
2010年 | 10660篇 |
2009年 | 14536篇 |
2008年 | 6324篇 |
2007年 | 4529篇 |
2006年 | 6940篇 |
2005年 | 4267篇 |
2004年 | 3432篇 |
2003年 | 2370篇 |
2002年 | 2483篇 |
2001年 | 4000篇 |
2000年 | 3217篇 |
1999年 | 3414篇 |
1998年 | 3757篇 |
1997年 | 3544篇 |
1996年 | 3447篇 |
1995年 | 3291篇 |
1994年 | 2021篇 |
1993年 | 1629篇 |
1992年 | 1520篇 |
1991年 | 1541篇 |
1990年 | 1209篇 |
1989年 | 1284篇 |
1988年 | 1141篇 |
1987年 | 969篇 |
1986年 | 1005篇 |
1985年 | 840篇 |
1984年 | 645篇 |
1983年 | 602篇 |
1982年 | 589篇 |
1981年 | 470篇 |
1980年 | 411篇 |
1979年 | 415篇 |
1978年 | 410篇 |
1977年 | 457篇 |
1975年 | 343篇 |
1972年 | 370篇 |
Method: First, persons assessed for admittance in 2005–2011 (n?=?127) were categorized into four trajectory groups based on whether they were admitted or denied (n?=?19), discharged (n?=?31), readmitted (n?=?21) or had been undergoing OMT without interruption (n?=?56). Second, 99 of these, the analytical sample, were interviewed at follow-up using (a) the Addiction Severity Index (ASI) for seven problem-areas and housing, and (b) self-rated change in 11 problem areas. The ASI was compared to baseline interviews after 55 months (mean). Third, outcomes within groups was studied in relation to alternative interventions.
Results: Within the analytical sample, those denied OMT showed no improvements at group level, those discharged had some improvements, more if readmitted than if not and those with uninterrupted OMT showed the most comprehensive improvements. Those outside OMT, denied and discharged, had considerable mortality risks related to ongoing drug use, especially in lack of well-planned alternative interventions.
Conclusion: Improvements strongly relate to access to OMT. This study underscores that access to OMT improves the situation in all areas investigated and decreases the risk for drug-related death. It underscores the importance of two major risk situations, i.e. being denied OMT and being discharged. 相似文献
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.